Modality
Fusion Protein
MOA
WEE1i
Target
JAK2
Pathway
Ferroptosis
AsthmaHuntington'sCLL
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
Dec 2022
→ Jan 2030
Phase 1Current
NCT08109980
2,418 pts·CLL
2023-03→2030-01·Completed
NCT03356323
2,365 pts·Asthma
2022-12→TBD·Completed
4,783 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-273.8y awayPh2 Data· CLL
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1/2
Complet…
P1/2
Complet…
Catalysts
Ph2 Data
2030-01-27 · 3.8y away
CLL
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08109980 | Phase 1/2 | CLL | Completed | 2418 | EASI-75 |
| NCT03356323 | Phase 1/2 | Asthma | Completed | 2365 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR | |
| Motanaritide | Intellia | Approved | PD-1 |